Judyth Vary Baker on AI, Power, and the Fight to Stay Human

In the third part of this series featuring Judyth Vary Baker on the Truth & Justice League Podcast, this episode delves into the intricacies of artificial intelligence and brings the realities of our future into the story. When the latest technologies are taken under governmental control, and the government is experimenting in their ability to persuade human nature and capitalize on surveillance and the collection of data, how do we protect ourselves and each other? Judyth’s history has been shaped by the subversive power of government entities. She and Mark go into detail on the reach and scope of DARPA, the Defense Advanced Research Projects Agency that is the center for computing, engineering, technical and scientific programs the U.S. uses for war. Judyth credits her fearlessness to experiments in spirituality, creating art, listening to music, and searching for what it really means to be human in the age of technology and AI. Music, art, poetry, religion, spirituality are all pathways humans can interact with another frequency, another realm and make you want to stay alive.---------Born in 1943, Judyth Vary Baker is an American artist, writer, poet, witness, cancer researcher and CEO & Founder of JFK Conferences, LLC. She has published several historical accounts and books of poetry including “Lee and Me and Lee: How I Came to Know, Love and Lose Lee Harvey Oswald,” “Kennedy & Oswald: The Big Picture,” biography “David Ferrie: Mafia Pilot” and “Letters to the Cyborgs” a work of science fiction based on today’s inventions and the AI crises, which includes a short story written by Oswald. She was silent for 35 years following Oswald’s death, and now continues to gain support from researchers that meet her and corroborate her story as more facts of JFK’s assassination have been released to the public. She worked with Dr. Alton Ochsner, a major figure in early cancer research, and continues her crusade today after being pushed out of the medical community in the 1960s, when funding shifted from curing cancer to treating it.